Here's some more details from the JAMA site. Interesting that they had good results even though the vaccine wasn't a good match to the strain that ended up circulating that season - indicates to me that this product has advantages over and above avoiding the "ouch."
Peter
Abstracts - July 14, 1999
Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working Adults
A Randomized Controlled Trial
Kristin L. Nichol, MD, MPH
Paul M. Mendelman, MD
Kenneth P. Mallon, MS, MHS
Lisa A. Jackson, MD, MPH
Geoffrey J. Gorse, MD
Robert B. Belshe, MD
W. Paul Glezen, MD
Janet Wittes, PhD
for the Live Attenuated Influenza Virus Vaccine in Healthy Adults Trial Group
Context Influenza virus is a major cause of illness, disruption to daily life, and increased use of health care in all age groups.
Objective To assess the safety and effectiveness of intranasally administered trivalent, live, attenuated influenza virus (LAIV) vaccine for reducing illness, absenteeism, and health care use among healthy, working adults.
Design Randomized, double-blind, placebo-controlled trial conducted from September 1997 through March 1998.
Setting Thirteen centers across the United States.
Participants A total of 4561 healthy, working adults aged 18 to 64 years recruited through health insurance plans, at work sites, and from the general population.
Intervention Participants were randomized 2:1 to receive intranasally administered trivalent LAIV vaccine (n=3041) or placebo (n=1520) in the fall of 1997.
Main Outcome Measures Episodes of febrile illness, severe febrile illness, febrile upper respiratory tract illness, work loss, and health care use during the peak and total influenza outbreak periods, and adverse events.
Results Recipients of LAIV vaccine were as likely to experience 1 or more febrile illnesses as placebo recipients during peak outbreak periods (13.2% for vaccine vs 14.6% for placebo; P=.19). However, vaccination significantly reduced the numbers of severe febrile illnesses (18.8% reduction; 95% confidence interval [CI], 7.4%-28.8%) and febrile upper respiratory tract illnesses (23.6% reduction; 95% CI, 12.7%-33.2%). Vaccination also led to fewer days of illness across all illness syndromes (22.9% reduction for febrile illnesses; 27.3% reduction for severe febrile illnesses), fewer days of work lost (17.9% reduction for severe febrile illnesses; 28.4% reduction for febrile upper respiratory tract illnesses), and fewer days with health care provider visits (24.8% reduction for severe febrile illnesses; 40.9% reduction for febrile upper respiratory tract illnesses). Use of prescription antibiotics and over-the-counter medications was also reduced across all illness syndromes. Vaccine recipients were more likely to experience runny nose or sore throat during the first 7 days after vaccination, but serious adverse events between the groups were not significantly different. The match between the type A(H3N2) vaccine strain and the predominant circulating virus strain (A/Sydney/05/97[H3N2]) for the 1997-1998 season was poor, suggesting that LAIV provided substantial cross-protection against this variant influenza A virus strain.
Conclusion Intranasal trivalent LAIV vaccine was safe and effective in healthy, working adults in a year in which a drifted influenza A virus predominated.
JAMA. 1999;282:137-144
|
